Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and m…
$29.82+3.65%
报价 2026-11-06
市值
$2.23B
EV
$1.99B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -8.5%
$11.07$32.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 0.9x | -0.79 → -1.45 | — |
| FY+32028-12 | 1.0x | -0.79 → -0.91 | — |
毛利率 59% · TTM 收入 $269M · 基数 EPS -0.79（调整后）
电话会信号
辅助标签Q3 20262026-11-04
AI 词频高上调指引
指引 上调
信心 4
分析师 4
“We now expect full year 2026 ACV of $222 million to $232 million, representing 12% to 17% growth over 2025.”
原文引用（1）
- 上调指引：On the strength of this performance, we are raising our full year guidance for both ACV and drug discovery revenue.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SDGRSchrödinger, Inc. | $2.23B | +3.6% | -4.3% | 59.3% | – | – | – | |
| TXG10x Genomics, Inc. | $7.13B | +2.1% | -2.5% | 74.5% | – | 204.2x | 66.8x | |
| ABCLAbCellera Biologics Inc. | $3.85B | +6.7% | – | 75% | – | – | – | |
| PGNYProgyny, Inc. | $2.67B | +1.4% | +7.6% | 24.5% | 30.3x | 18.4x | 12.2x | |
| IMNMImmunome, Inc. | $2.21B | +4.5% | -67.5% | -1,161.9% | – | – | – | |
| AZTAAzenta, Inc. | $1.72B | +4.8% | +4.0% | 44.9% | – | – | 173.6x | |
| OMCLOmnicell, Inc. | $1.7B | -1.8% | +3.8% | 44.8% | 38.3x | 10.5x | 11.7x | |
| TDOCTeladoc Health, Inc. | $1.6B | -6.8% | -4.1% | 68.6% | – | 7.5x | 6.9x | |
| OMDAOmada Health | $923.8M | -20.4% | +33.4% | 75.9% | 169.6x | 40.3x | 32.8x | 高增长 |
| 同行中位数 | – | – | +3.8% | 56.7% | 38.3x | 18.4x | 22.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $64.5M | $58.9M | $58.6M | $87.2M | $54.3M | $54.8M | $59.6M | $88.3M |
| Gross Margin | 59.3% | 55.1% | 50.4% | 65.7% | 51.6% | 47.8% | 52.3% | 72.6% |
| Operating Margin | -40.5% | -70.6% | -83.3% | -19.7% | -84.6% | -96.6% | -85.5% | -23.5% |
| Net Income | $-37.7M | $6M | $-60M | $32.5M | $-32.8M | $-43.2M | $-59.8M | $-40.2M |
| Diluted EPS | -0.5 | 0.08 | -0.81 | 0.44 | -0.45 | -0.59 | -0.82 | -0.55 |
| Operating Cash Flow | $-145.4M | $63.7M | $-14.8M | $-16.1M | $-61.9M | $-52.2M | $144.1M | $-31.1M |